Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy
about
ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD - SummaryFirst-line drugs inhibiting the renin angiotensin system versus other first-line antihypertensive drug classes for hypertensionAldosterone antagonists for preventing the progression of chronic kidney diseaseProbucol for type 2 diabetes mellitusProstaglandin E1 for preventing the progression of diabetic kidney diseaseAldosterone antagonists for preventing the progression of chronic kidney diseaseProbucol for type 2 diabetes mellitusFirst-line drugs inhibiting the renin angiotensin system versus other first-line antihypertensive drug classes for hypertensionAldosterone antagonists for preventing the progression of chronic kidney diseaseAngiotensin converting enzyme inhibitors and angiotensin II receptor antagonists for preventing the progression of diabetic kidney diseaseAdvanced glycation end-products induce calpain-mediated degradation of ezrinProtein microarrays discover angiotensinogen and PRKRIP1 as novel targets for autoantibodies in chronic renal diseaseAngiotensin receptor blockers and myocardial infarctionStandards of medical care in diabetes--2012Avosentan reduces albumin excretion in diabetics with macroalbuminuriaAccess to health care among status Aboriginal people with chronic kidney diseaseSupramaximal dose of candesartan in proteinuric renal diseaseAddition of angiotensin receptor blockade or mineralocorticoid antagonism to maximal angiotensin-converting enzyme inhibition in diabetic nephropathyGuidelines for the management of chronic kidney diseasePolymorphism of the ACE Gene in dialysis patients: overexpression of DD genotype in type 2 diabetic end-stage renal failure patientsInformative noncompliance in endpoint trialsLosartan and diabetic nephropathy: commentaries on the RENAAL studyNeurohumoral stimulation in type-2-diabetes as an emerging disease conceptA novel approach to treatment of hypertension in diabetic patients - a multicenter, double-blind, randomized study comparing the efficacy of combination therapy of Eprosartan versus Ramipril with low-dose Hydrochlorothiazide and Moxonidine on bloodPilot study of losartan for pulmonary hypertension in chronic obstructive pulmonary disease.Determinants of persistence in hypertensive patients treated with irbesartan: results of a postmarketing survey.Common angiotensin receptor blockers may directly modulate the immune system via VDR, PPAR and CCR2bNew Pathogenic Concepts and Therapeutic Approaches to Oxidative Stress in Chronic Kidney DiseaseTranscriptomics: A Step behind the Comprehension of the Polygenic Influence on Oxidative Stress, Immune Deregulation, and Mitochondrial Dysfunction in Chronic Kidney DiseaseOxidative Stress in Diabetic Nephropathy with Early Chronic Kidney DiseaseContinued efforts to translate diabetes cardiovascular outcome trials into clinical practiceRecent advances in managing and understanding diabetic nephropathyProteomics for prediction of disease progression and response to therapy in diabetic kidney diseaseEffect of antihypertensive treatment at different blood pressure levels in patients with diabetes mellitus: systematic review and meta-analysesDiabetes mellitus as a compelling indication for use of renin angiotensin system blockers: systematic review and meta-analysis of randomized trialsRecommendations for the use of tolvaptan in autosomal dominant polycystic kidney disease: a position statement on behalf of the ERA-EDTA Working Groups on Inherited Kidney Disorders and European Renal Best PracticeCardiovascular and Renal Outcomes of Renin-Angiotensin System Blockade in Adult Patients with Diabetes Mellitus: A Systematic Review with Network Meta-AnalysesRole of Bone Marrow-Derived Fibroblasts in Renal FibrosisThe Different Therapeutic Choices with ARBs. Which One to Give? When? Why?Autophagy: A Novel Therapeutic Target for Diabetic Nephropathy
P2860
Q22241786-B62887CC-B050-4CEE-B1D2-DE3D23FF2608Q24186647-B1AAD855-D51D-4759-8DA6-A65FE6F06FC9Q24194979-004DC825-03E1-44FE-964E-3FA349FB1083Q24195163-5B88C411-6580-40C2-9774-8FADB5F9F947Q24235251-6805AEAE-ECB7-46EE-83DB-6C54A6288B0DQ24239909-7D2100FD-0A93-4EAC-B7C3-123189F5C90DQ24240606-F9FF4D3A-4F3D-49F3-B642-95D87F87ACBEQ24240851-84DA3D06-7A4E-4A3D-9F5B-19963F589FB9Q24243615-A614B066-BE18-42A9-A32E-A2F748F4A61DQ24244197-CE230A41-C18B-4CB3-9A8F-67141057887EQ24293645-F0BED107-190E-41E3-9095-DE9B08395D77Q24320230-24A3CCB5-2116-4555-AAB6-E6BC2060C1B3Q24559659-1E64803A-5C60-454B-A7D4-CCF3BC8DBFF7Q24632533-36B444BB-0491-42E8-A309-C78EB67D88DAQ24642372-5BF0F827-6491-4685-BB42-6F1875D5C324Q24648683-F355DB82-D030-4A71-94C1-78C454BD8D07Q24649685-AF7B5EC0-8F0F-498A-8360-DC4284F5D1D4Q24657470-44972AFC-AC5B-43BC-89DD-0C9B042C028EQ24657844-F0403C22-C5B9-4B21-B5E7-BED3A20D7203Q24658206-1484C142-40D2-4D31-A6DA-22920F9EB255Q24791524-DCC886D1-9D4C-49BB-9235-983A6EDF3FE9Q24796010-D9E90D84-B3B5-4459-9A29-4A5BF52F7165Q24798310-6FF4BBEF-C40B-46E6-A713-A82B8BCB4E00Q24806038-66A702F0-680E-4E83-B0D8-835BEF611CE1Q24811026-DB539E58-21A5-4A42-AD29-6FE3E1AE55CAQ24814563-6BB09F9F-3D31-4CF3-BA7A-9445CA182C3AQ25257883-889265FB-0CE5-4FCC-AB42-9B46B850FAF3Q26739475-A9F05AAF-A967-4CB3-9661-2C4779F480E5Q26740125-F26496C5-31FA-45C3-B567-C53E09961DCFQ26741451-D5192DEF-756A-46A3-A05D-BBCDC2C768C6Q26741860-F71DCFF1-76C6-4258-A374-3FD64B4DCB2CQ26745900-FC893472-BEBC-4BF9-A281-31A3988BDE09Q26747131-20C1EDAB-ACE4-4453-821E-15FBCF4A6A94Q26766025-73B14E30-BECF-4125-A65C-C96B9E17B240Q26766599-C908E0EE-CBC7-432F-900F-D2ED094C8027Q26767011-7319EAFF-B0BD-45ED-BAF2-99E89254DB54Q26767278-211A80B3-32ED-4977-8654-948540B282A4Q26768585-80AE872C-44DC-4454-B10D-C52A7553AFF9Q26768696-24B86C9F-82DF-45CB-8822-63E809DA5442Q26771919-83254E7C-7AEB-4733-B285-D580008784CC
P2860
Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy
description
2001 nî lūn-bûn
@nan
2001 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Effects of losartan on renal a ...... ype 2 diabetes and nephropathy
@ast
Effects of losartan on renal a ...... ype 2 diabetes and nephropathy
@en
type
label
Effects of losartan on renal a ...... ype 2 diabetes and nephropathy
@ast
Effects of losartan on renal a ...... ype 2 diabetes and nephropathy
@en
prefLabel
Effects of losartan on renal a ...... ype 2 diabetes and nephropathy
@ast
Effects of losartan on renal a ...... ype 2 diabetes and nephropathy
@en
P2093
P3181
P356
P1476
Effects of losartan on renal a ...... ype 2 diabetes and nephropathy
@en
P2093
Brenner BM
Parving HH
Shahinfar S
Snapinn SM
de Zeeuw D
P3181
P356
10.1056/NEJMOA011161
P407
P577
2001-09-20T00:00:00Z